FDA, IBM Watson Health to study use of blockchain in health data exchange

FDA and IBM Watson Health have entered a two-year partnership to study the efficacy of health data exchange using blockchain technology.

The research initiative seeks to determine whether blockchain, which is known for its accountability and security, can be leveraged for secure, patient-controlled data sharing, including the exchange of data from sources like EMRs, clinical trials, genomic data, wearables and the Internet of Things. For example, consumers may be able to use blockchain technology to share data from wearables with researchers and providers, which could help facilitate developments in public health.

FDA and IBM Watson Health, which will focus their initial research on oncology data, plan to share their preliminary findings in 2017.

More articles on health IT:
Study: Do privacy concerns encourage patients to withhold health information?
Illumina taps IBM Watson for cancer data interpretation
Survey: 49% of health IT professionals worry about inappropriate employee use of mobile devices

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers